Taysha Gene Therapies (TSHA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Taysha Gene Therapies

NasdaqGS•Healthcare•Biotechnology

$5.34-0.14(-0.03%)After hours

Market Cap

$1.85B

P/S

337.8x

P/B

4.8x

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

How this company scores

AverageMetricSide Score: 40/100

Strongest: Balance Sheet & Red Flags (21/25); weakest: Growth (5/25).

Profitability8/25

Growth5/25

Balance Sheet & Red Flags21/25

Cash & Earnings Quality6/25

Strengths

Long cash runwayLow leverageImproving leverageNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 337.8x5y range 4.4x – 337.8x

Currently above its 15-quarter median.

P/B · 4.8x5y range 2.7x – 104.7x

Currently near its 17-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.85B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $5.49M
Q. Revenue: $0
TTM EBITDA: $-151.90M
TTM Op. Income: $-153.16M
Q. Op. Income: $-47.35M
TTM Net Income: $-149.63M
Q. Net Income: $-46.64M
EPS: $-0.13
Shares Out.: $369.04M

$5.49M in TTM revenue declined 32.3% YoY, reaching $0 last quarter. TTM EBITDA of $-151.90M and TTM operating income of $-153.16M show growth is flowing through to the bottom line. However, net income is negative at $149.63M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 3 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -4734900000.0%
Net Margin: -4663900000.0%

Op. margin of -4734900000.0% is down 4734898652.9% YoY — costs are rising relative to revenue. Net margin at -4663900000.0% Across the last 8 quarters, operating margin has fallen for 3 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 337.8x
P/B Ratio: 4.8x

P/S of 337.8x and P/B of 4.8x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $470.43M
Cash: $455.41M
Long-Term Debt: $49.26M
Book Value: $387.27M
D/E Ratio: 0.1
Debt/EBITDA: N/A

With $470.43M in assets and $49.26M in long-term debt, D/E is 0.1and book value is $387.27M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 23% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-40.42M
TTM Free Cash Flow: $-132.57M
FCF Margin: -2417.0%
FCF / Net Income: 0.9

TTM FCF of $-132.57M on $-40.42M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 4 consecutive quarters — a weakening trend.